Next Article in Journal
Delusional Parasitosis Impeding Delivery of Acute Care in a Cancer Patient
Previous Article in Journal
Polyphenol Extracts from Red Wine and Grapevine: Potential Effects on Cancers
Open AccessArticle

DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines

1
The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), Roosevelt Drive, Oxford OX3 7BN, UK
2
Department of Immunology, RIA, Inselspital, University of Bern, Sahlihaus 1/2, 3010 Bern, Switzerland
3
Bencard Adjuvant Systems, Dominion Way, Worthing BN14 8SA, UK
4
Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
*
Authors to whom correspondence should be addressed.
These authors contribute equally to this work.
Diseases 2018, 6(4), 107; https://doi.org/10.3390/diseases6040107
Received: 28 September 2018 / Revised: 12 November 2018 / Accepted: 16 November 2018 / Published: 21 November 2018
(This article belongs to the Special Issue Vaccines as Allies in the Malaria Eradication Effort)
Vaccination remains the most effective and essential prophylactic tool against infectious diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes remain so far limited. Novel adjuvants may offer a significant advantage in the development of malaria vaccines, in particular if combined with inherently immunogenic platforms, such as virus-like particles (VLP). Dioleoyl phosphatidylserine (DOPS), which is expressed on the outer surface of apoptotic cells, represents a novel adjuvant candidate that may confer significant advantage over existing adjuvants, such as alum. In the current study we assessed the potential of DOPS to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using Plasmodium falciparum thrombospondin-related adhesive protein (TRAP) as a target antigen. TRAP was chemically coupled to VLPs derived from the cucumber mosaic virus fused to a universal T cell epitope of tetanus toxin (CuMVtt). Mice were immunized with TRAP alone or formulated in alum or DOPS and compared to TRAP coupled to CuMVtt formulated in PBS or DOPS. Induced immune responses, in particular T cell responses, were assessed as the major protective effector cell population induced by TRAP. The protective capacity of the various formulations was assessed using a transgenic Plasmodium berghei expressing PfTRAP. All vaccine formulations using adjuvants and/or VLP increased humoral and T cell immunogenicity for PfTRAP compared to the antigen alone. Display on VLPs, in particular if formulated with DOPS, induced the strongest and most protective immune response. Thus, the combination of VLP with DOPS may harness properties of both immunogenic components and optimally enhance induction of protective immune responses. View Full-Text
Keywords: vaccine; adjuvants; Plasmodium falciparum; malaria; virus like particle (VLP); dioleoyl phosphatidylserine (DOPS) vaccine; adjuvants; Plasmodium falciparum; malaria; virus like particle (VLP); dioleoyl phosphatidylserine (DOPS)
Show Figures

Figure 1

MDPI and ACS Style

Cabral-Miranda, G.; M. Salman, A.; O. Mohsen, M.; L. Storni, F.; S. Roesti, E.; A. Skinner, M.; D. Heath, M.; F. Kramer, M.; M. Khan, S.; J. Janse, C.; V. S. Hill, A.; F. Bachmann, M. DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases 2018, 6, 107.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop